Semaglutide is a GLP-1 receptor agonist primarily used as a treatment for diabetes (Ozempic, Novo Nordisk) and more recently greenlit as a breakthrough treatment for obesity (Wegovy, Novo Nordisk)
Godfrey H, Leibovit-Reiben Z, Jedlowski P, et al
Senators repeatedly asked why Novo Nordisk, the maker of Ozempic and Wegovy, charges over $1,000 (746) in the US for the same drug it charges just $92 for in Germany
How much does dry mouth affect your ability to speak
Under physiological conditions, renal tubular epithelial cells highly express the carnitine transporter OCTN2 (SLC22A5), which mediates active reabsorption of filtered carnitine with an efficiency exceeding 95%
Several mechanisms may explain how GLP-1 therapy could theoretically influence bone health, though the clinical significance of these pathways remains under investigation